The BAP is a learned society and registered charity. It promotes research and education in psychopharmacology and related areas, and brings together people in academia, health services, and industry. Formed in 1974, it is the largest such national association in Europe, and the second largest in the world.

Read more about BAP

2019 Prizes and Awards

View photos, reflections and biographies from this year's prize winners. Continually updated, so check back often.
Read More

Pocket Prescriber Psychiatry

The new Pocket Prescriber Psychiatry book is out now.
Read More

Visualising Psychotropic Medicine (VPM)

Presenting what can be a complex set of data in a useful and engaging way
Read More

Online CPD Resource

RCPsych Online CPD Subscribers get a discount on the BAP Online Resource
Read More

Fundamentals of Clinical Psychopharmacology

Buy a discounted copy of the latest edition of Fundamentals of Clinical Psychopharmacology
Read More

The Ten Secrets of Success in Science

View Professor Trevor Robbins presenting his top tips
Read More

Neuroscience-based Nomenclature (NbN) for JoP

Journal of Psychopharmacology chosen to trial new NbN
Read More

Fundamentals Wins BMA Award

Fundamentals of Clinical Psychopharmacology wins BMA Medical Book Award in Psychiatry
Read More

Not all in the mind – the contribution of brain science to modern psychiatry

Watch Prof David Nutt's lecture in Manchester on YouTube
Read More

Membership

Benefits of BAP membership include:

  • FREE subscription and access to the Journal of Psychopharmacology (published monthly online).
  • Reduced registration fees for the annual Summer Meeting.
  • Half price subscription to the Online CPD Resource.
  • Eligibility for prizes and awards.
  • Student bursaries for the BAP Summer Meeting and international conferences.
  • Reduced registration fees for selected partner association events.
  • 50% OFF Royal Society of Biology membership (Read more)
  • BAP Newsletter.
  • Voting for BAP Officers and Council (full members only).
  • Being part of one of the largest national psychopharmacology associations in the world.

Meetings and Events

All Events

7th September 2019 32nd ECNP Congress Copenhagen
10th September 2019 IoPPN 19th Maudlsey Forum 2019 King’s College London
12th September 2019 Drug Treatments in Affective Disorders The International Centre for Life (Conferences), Newcastle upon Tyne

Clinical Certificate | Masterclasses | Non-Clinical Certificate

Articles

Symposium 8 – The orexinergic system of the brain and its importance for neuropsychiatry
By Kristi Sawyer
Posted on 20th July 2019

Chaired by: Professor Elemer Szabadi (Nottingham) Professor Jyrki Kukkonen (Helsinki): Neuroanatomy and physiology of the orexinergic system. Professor Kukkonen kicked-off this session on Wednesday morning by giving us a comprehensive overview of the orexinergic system. We learned that orexins were discovered by 2 groups independently, within weeks of each other, around 20 years ago, in […]


Psychopharmacology Awards – Winners’ Short Orals
By Alexandra Pike
Posted on 19th July 2019

This session, in which winners of the Psychopharmacology Awards present their work, always has high attendance and this year was no exception. Dr Tom Freeman, the winner of the junior non-clinical award, presented on the role of cannabinoids in the development and treatment of addiction. He noted that recent policy changes in the UK have […]


Symposium 7 – What do computational models tell us about cognition in depression and psychosis?
By Ellie Smith
Posted on 19th July 2019

This symposium discussed how computational models could be used to explore decision-making and prediction learning in psychiatric disorders. By including computational modelling in our analyses we can identify and quantify key parameters, which are not visible to traditional analyses, and can often be successfully linked to the function of underlying neural systems or to clinically […]


See more articles

Media

Annabel Walsh (MQ IDEA Project)
MQ Open Mind Podcast
Helen Fisher and MQ ambassador John discuss risk for developing depression and the Identifying Depression Early in Adolescence (IDEA) Project.
29th July 2019

Barbara Sahakian
Understanding the infant-parent connection: summary interview
Barbara Sahakian interviews developmental cognitive neuroscientist Dr Victoria Leong about her research with mothers and babies exploring how they naturally synchronise during social interactions, helping babies learn from their mothers.
26th July 2019

Naomi Fineberg (International COST Action CA16207)
Is excessive use of social media an addiction?
International COST Action CA16207 is a research focussed network on problematic internet addiction. Covered by ABC News
3rd May 2019

David Nutt
Psychedelics, addiction, and mental health
David talks to ABC Radio National about psychedelics, addiction, and mental health
24th February 2019

Stephen Lawrie
Hollywood past saves climber Hamish MacInnes from dementia death sentence
Stephen was quoted in the Times article about how Hamish MacInnes recovered from Dementia with the help of his films and books
22nd February 2019

See more media

News

2019 Prizes and Awards
25th July 2019

View all award winners from this year's meeting. Photos, reflections and biographies are being continually updated, so check back often.
View this year's prize winners
Street Drugs Conference Wales 2019: Is the Dragon Still Smoking?
13th July 2019

Overview of the latest Street Drugs Conference in Wales on 25th June.
Read the review
REF2021 Success
4th February 2019

Prof Allan Young, Prof Jeremy Hall and Prof Helen Cassaday selected to join REF2021 panel 4: Psychology, Psychiatry and Neuroscience
Read More
Professor David Nutt Wins Academic Honorary Award in Istanbul
9th November 2018

Professor David Nutt has won the Academic Honorary Award at the International Crime and Punishment Film Festival in Istanbul
Read More

See more news

Twitter


Psychopharmacology is the study of drugs that affect mood, behaviour and cognition. It aims to develop our understanding of the actions and effects of such drugs, which may include treatments for psychiatric disorders as well as substances that can be abused.